MORE►
Thomas Tull
Dr. Beth Shapiro and Colossal Co-Founder and CEO Ben Lamm with a stuffed dodo. [Photo: Colossal]
Texas-Based Colossal Achieves Unicorn Status With $150M Series B Raise, Plans To ‘De-Extinct’ the Dodo Bird
by David Seeley | Jan 31, 2023
Colossal says its efforts could help boost "the U.S. high-tech advantage." Its gene editing technologies "will make waves across sectors—in agriculture with new biofuels and preserving biodiversity, as well as in human health through improved gene therapy and vaccine development," the company said.
by Kevin Cummings |
Sep 30, 2022
In this week’s North Texas deal flow, you’ll also find news about crowdfunding platform Harvest Return landing $2.5M; Supply’s acquisition by Foundry Brands; Moss Adams acquiring local CPA firm Kurtz & Company P.C.; Tri Global Energy being acquired for $270M by Canada's Enbridge; and more.
MORE►
by Kevin Cummings |
Sep 27, 2022
Dallas-based Colossal Biosciences, the de-extinction company behind plans to bring back the woolly mammoth and thylacine, developed its own software solution "after reviewing everything available on the market." Now it's sharing the platform with the launch of Form Bio.
The spinout's technology tools can help drive the “entire molecular revolution” that is occurring in the life sciences and biotech space, in addition to bolstering the Lone Star state as a hub for the industry, says Chief Strategy Officer Claire Aldridge.
The spinout's technology tools can help drive the “entire molecular revolution” that is occurring in the life sciences and biotech space, in addition to bolstering the Lone Star state as a hub for the industry, says Chief Strategy Officer Claire Aldridge.
MORE►
by Kevin Cummings |
Mar 21, 2022
What companies are finding funding or having a big exit? From startup investments to grants and acquisitions, Dallas Innovates tracks what’s happening in North Texas money.
MORE►
